Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cluster headaches

- PMLiVE

Lilly asks to revoke emergency authorisation for bamlanivimab monotherapy in the US

Decision prompted by the ‘evolving variant landscape’ in the US

- PMLiVE

Lilly’s RET inhibitor Retevmo shows early promise in new cancer types

Trial included patients with pancreatic, colon, breast and salivary cancer

- PMLiVE

Lilly, Vir and GSK’s antibodies reduce viral load by 70% in low-risk COVID-19 patients

The two neutralising antibodies bind to different epitopes of the SARS-CoV-2 spike protein

- PMLiVE

Lilly reports positive data from its phase 3 ulcerative colitis trial

IL-23 blocker mirikizumab helped patients achieve clinical remission in 12-week induction study

- PMLiVE

Lilly to expand donanemab study in a bid for approval in Alzheimer’s disease

Lilly revealed expanded findings from phase 2 TRAILBLAZER-ALZ study this week

- PMLiVE

EMA starts rolling review of Lilly’s COVID-19 antibodies

CHMP will review the combination of bamlanivimab and etesemivab as well as bamlanivimab monotherapy

- PMLiVE

Lilly partners with Biolojic Design to develop diabetes antibody therapies

Agreement could be worth up to $121m in milestone payments

- PMLiVE

EMA recommends use of Lilly’s COVID-19 antibody cocktail

Agency concludes bamlanivimab and etesevimab can be used to treat certain COVID-19 patients

- PMLiVE

Lilly’s tirzepatide shows superiority over Novo’s semaglutide in type 2 diabetes trial

Lilly's drug beat semaglutide 1mg on multiple measures including weight loss

- PMLiVE

Lilly signs $960m deal with Rigel to develop RIPK1 inhibitors

Companies will co-develop molecules for the treatment of immunological and neurodegenerative diseases

- PMLiVE

Three strategies for managing loss of exclusivity successfully

Consultant, Claire Taylor explains why you should be strategically planning your LOE strategy years in advance.

Blue Latitude Health

- PMLiVE

FDA grants emergency use for Lilly’s COVID-19 antibody drug combination

Bamlanivimab plus etesevimab shown to reduce risk of death in high-risk COVID-19 patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links